- Home
- VOXR vs PBYI Comparison
VOXR vs PBYI Comparison
Compare VOXR & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOXR
- PBYI
- Stock Information
- Founded
- VOXR 2014
- PBYI 2010
- Country
- VOXR Canada
- PBYI United States
- Employees
- VOXR N/A
- PBYI N/A
- Industry
- VOXR Precious Metals
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- VOXR Basic Materials
- PBYI Health Care
- Exchange
- VOXR Nasdaq
- PBYI Nasdaq
- Market Cap
- VOXR 126.5M
- PBYI 126.5M
- IPO Year
- VOXR N/A
- PBYI N/A
- Fundamental
- Price
- VOXR $2.76
- PBYI $2.91
- Analyst Decision
- VOXR
- PBYI Strong Buy
- Analyst Count
- VOXR 0
- PBYI 1
- Target Price
- VOXR N/A
- PBYI $7.00
- AVG Volume (30 Days)
- VOXR 277.5K
- PBYI 557.7K
- Earning Date
- VOXR 11-06-2024
- PBYI 11-07-2024
- Dividend Yield
- VOXR 1.75%
- PBYI N/A
- EPS Growth
- VOXR N/A
- PBYI 492.79
- EPS
- VOXR N/A
- PBYI 0.47
- Revenue
- VOXR $11,147,864.00
- PBYI $243,569,000.00
- Revenue This Year
- VOXR $1.91
- PBYI N/A
- Revenue Next Year
- VOXR $8.94
- PBYI N/A
- P/E Ratio
- VOXR N/A
- PBYI $6.06
- Revenue Growth
- VOXR N/A
- PBYI 6.30
- 52 Week Low
- VOXR $1.70
- PBYI $2.23
- 52 Week High
- VOXR $3.24
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- VOXR 43.42
- PBYI 49.25
- Support Level
- VOXR $2.43
- PBYI $2.32
- Resistance Level
- VOXR $2.79
- PBYI $3.25
- Average True Range (ATR)
- VOXR 0.11
- PBYI 0.31
- MACD
- VOXR -0.01
- PBYI -0.03
- Stochastic Oscillator
- VOXR 49.06
- PBYI 42.86
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of over 60 royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.